Systemic Therapy for Colon Cancer

Abstract

Systemic treatments for patients with colon cancer has expanded broadly beyond 5-fluorouracil based chemotherapy. For early stage colon cancer patients who are considering adjuvant chemotherapy, multiple factors such as the risk of disease recurrence, absolute survival benefit of chemotherapy, treatment toxicity, and patient comorbid medical conditions must be taken into account. In the metastatic setting, biomarkers such as KRAS/NRAS/BRAF mutation, microsatellite instability status, and left- versus right-sided colon cancer have helped oncologists to tailor systemic treatment regimens, which include chemotherapy, targeted therapy, and immunotherapy.

Keywords: 5-fluorouracil; Antiepidermal growth factor receptor antibody; Immunotherapy; Irinotecan; Oxaliplatin; Regorafenib; Trifluridine/tipiracil; Vascular endothelial growth factor antibody.